Market Overview:
The global retinal biologics market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of eye diseases, such as macular degeneration, diabetic retinopathy, and uveitis. In addition, the increasing demand for novel therapies and growing awareness about available treatments are also contributing to the growth of this market. Based on type, the global retinal biologics market is segmented into macular degeneration, diabetic retinopathy, diabetic macular edema (DME), uveitis, and others. Macular degeneration is estimated to account for the largest share of this market in 2018 owing to its high prevalence among older adults. Based on application, hospitals are estimated to account for the largest share of this market in 2018 followed by clinics.
Product Definition:
Retinal biologics are treatments that use living cells, tissues, or organs to improve or restore vision. Retinal biologics may be used to treat conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and Stargardt's disease.
Macular Degeneration:
Macular degeneration is a progressive disorder of the macula, which is located in the center of the retina. The retina consists of photoreceptors and nerve fiber that connects to brain areas responsible for processing visual information. As light exposure increases, so does risk for developing age-related macular degeneration (AMD). AMD can be classified into two types: dry type and wet type.
Diabetic Retinopathy:
Diabetic retinopathy is a progressive eye disease that develops when high blood sugar (hyperglycemia) damages the retina and leads to loss of vision. Diabetic retinopathy generally affects people with diabetes mellitus who have a long history of high blood sugar. The longer the person has had diabetes, the more likely he/she is to develop diabetic retinopathy.
Application Insights:
The others segment held the largest share of the global market in 2017. This segment includes diabetic retinopathy, diabetic macular edema, uveitis and others. Retinal diseases are among the most common ophthalmic conditions across all age groups globally. According to Eye Bank Association of America, around 675000 patients are diagnosed with some form of eye disease every year in U.S., which is expected to rise to over 803000 by 2030 due to aging population and increase in lifestyle-related disorders such as obesity and diabetes mellitus type 2.
Diabetic retinopathy is expected register a significant growth rate during forecast period owing to its high prevalence rate coupled with increasing adoption of advanced therapies for its treatment such as laser photocoagulation.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing government funding for retinal care and development of novel therapies, such as artificial retina and stem cells. In addition, rising prevalence of eye-related disorders is also anticipated to drive regional growth over the forecast period. Asia Pacific is estimated to be fastest-growing region from 2018 to 2030 owing to improving healthcare infrastructure & availability of advanced treatment options at affordable costs in emerging countries, such as China & India.
Major companies include Bausch + Lomb; Cipla; Dr Reddy's Laboratories Ltd.; FzioMed; Iffco International Holdings BV; Novartis AG.; Ophtecs Corporation Pvt Ltd.; Roche Products S.A.; Takeda Pharmaceuticals International Co.
Growth Factors:
- Increasing prevalence of retinal diseases: The global prevalence of retinal diseases is increasing rapidly due to the aging population and rising incidence of diabetes. This is expected to drive the demand for Retinal Biologics products in the coming years.
- Growing awareness about Retinal Biologics therapies: There is a growing awareness among patients and healthcare professionals about the benefits of Retinal Biologics therapies for treating various retinal diseases. This is likely to boost demand for these products in the near future.
- Technological advancements in Retinal Biologics products: The technological advancements in RetinaBiologcs products are helping to improve their efficacy and safety profile, thus driving their adoption worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Retinal Biologics Market Research Report
By Type
Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, Uveitis, Others
By Application
Hospitals, Clinics, Others
By Companies
Spark Therapeutics, Inc, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc, AbbVie Inc, Johnson & Johnson Services, Inc, Amgen Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
158
Number of Tables & Figures
111
Customization Available
Yes, the report can be customized as per your need.
Global Retinal Biologics Market Report Segments:
The global Retinal Biologics market is segmented on the basis of:
Types
Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, Uveitis, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Spark Therapeutics, Inc
- F. Hoffmann-La Roche Ltd
- Regeneron Pharmaceuticals, Inc
- AbbVie Inc
- Johnson & Johnson Services, Inc
- Amgen Inc
Highlights of The Retinal Biologics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Macular Degeneration
- Diabetic Retinopathy
- Diabetic Macular Edema
- Uveitis
- Others
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Retinal Biologics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Retinal biologics are medications that are delivered directly to the eye. They help improve vision by restoring or maintaining the health of the retina.
Some of the major players in the retinal biologics market are Spark Therapeutics, Inc, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc, AbbVie Inc, Johnson & Johnson Services, Inc, Amgen Inc.
The retinal biologics market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Retinal Biologics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Retinal Biologics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Retinal Biologics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Retinal Biologics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Retinal Biologics Market Size & Forecast, 2018-2028
4.5.1 Retinal Biologics Market Size and Y-o-Y Growth
4.5.2 Retinal Biologics Market Absolute $ Opportunity
Chapter 5 Global Retinal Biologics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Retinal Biologics Market Size Forecast by Type
5.2.1 Macular Degeneration
5.2.2 Diabetic Retinopathy
5.2.3 Diabetic Macular Edema
5.2.4 Uveitis
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Retinal Biologics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Retinal Biologics Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Retinal Biologics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Retinal Biologics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Retinal Biologics Analysis and Forecast
9.1 Introduction
9.2 North America Retinal Biologics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Retinal Biologics Market Size Forecast by Type
9.6.1 Macular Degeneration
9.6.2 Diabetic Retinopathy
9.6.3 Diabetic Macular Edema
9.6.4 Uveitis
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Retinal Biologics Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Retinal Biologics Analysis and Forecast
10.1 Introduction
10.2 Europe Retinal Biologics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Retinal Biologics Market Size Forecast by Type
10.6.1 Macular Degeneration
10.6.2 Diabetic Retinopathy
10.6.3 Diabetic Macular Edema
10.6.4 Uveitis
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Retinal Biologics Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Retinal Biologics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Retinal Biologics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Retinal Biologics Market Size Forecast by Type
11.6.1 Macular Degeneration
11.6.2 Diabetic Retinopathy
11.6.3 Diabetic Macular Edema
11.6.4 Uveitis
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Retinal Biologics Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Retinal Biologics Analysis and Forecast
12.1 Introduction
12.2 Latin America Retinal Biologics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Retinal Biologics Market Size Forecast by Type
12.6.1 Macular Degeneration
12.6.2 Diabetic Retinopathy
12.6.3 Diabetic Macular Edema
12.6.4 Uveitis
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Retinal Biologics Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Retinal Biologics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Retinal Biologics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Retinal Biologics Market Size Forecast by Type
13.6.1 Macular Degeneration
13.6.2 Diabetic Retinopathy
13.6.3 Diabetic Macular Edema
13.6.4 Uveitis
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Retinal Biologics Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Retinal Biologics Market: Competitive Dashboard
14.2 Global Retinal Biologics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Spark Therapeutics, Inc
14.3.2 F. Hoffmann-La Roche Ltd
14.3.3 Regeneron Pharmaceuticals, Inc
14.3.4 AbbVie Inc
14.3.5 Johnson & Johnson Services, Inc
14.3.6 Amgen Inc
